BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fevery J, Verslype C, Lai G, Aerts R, Van Steenbergen W. Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci. 2007;52:3123-3135. [PMID: 17431781 DOI: 10.1007/s10620-006-9681-4] [Cited by in Crossref: 87] [Cited by in F6Publishing: 76] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Sinakos E, Lindor K. Treatment options for primary sclerosing cholangitis. Expert Review of Gastroenterology & Hepatology 2014;4:473-88. [DOI: 10.1586/egh.10.33] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
2 Thosani N, Banerjee S. Endoscopic Retrograde Cholangiopancreatography for Primary Sclerosing Cholangitis. Clinics in Liver Disease 2014;18:899-911. [DOI: 10.1016/j.cld.2014.07.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
3 Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ; American Association for the Study of Liver Diseases. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660-678. [PMID: 20101749 DOI: 10.1002/hep.23294] [Cited by in Crossref: 782] [Cited by in F6Publishing: 673] [Article Influence: 65.2] [Reference Citation Analysis]
4 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237-267. [PMID: 19501929 DOI: 10.1016/j.jhep.2009.04.009] [Cited by in Crossref: 1087] [Cited by in F6Publishing: 941] [Article Influence: 83.6] [Reference Citation Analysis]
5 Uko V, Thangada S, Radhakrishnan K. Liver disorders in inflammatory bowel disease. Gastroenterol Res Pract. 2012;2012:642923. [PMID: 22474447 DOI: 10.1155/2012/642923] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
6 Venkatesh PG, Navaneethan U, Shen B. Hepatobiliary disorders and complications of inflammatory bowel disease. J Dig Dis. 2011;12:245-256. [PMID: 21791019 DOI: 10.1111/j.1751-2980.2011.00511.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
7 Isayama H, Tazuma S, Kokudo N, Tanaka A, Tsuyuguchi T, Nakazawa T, Notohara K, Mizuno S, Akamatsu N, Serikawa M, Naitoh I, Hirooka Y, Wakai T, Itoi T, Ebata T, Okaniwa S, Kamisawa T, Kawashima H, Kanno A, Kubota K, Tabata M, Unno M, Takikawa H; PSC guideline committee Members: Ministry of Health, Labour and Welfare (Japan) Research Project, The Intractable Hepatobiliary Disease Study Group. Clinical guidelines for primary sclerosing cholangitis 2017. J Gastroenterol. 2018;53:1006-1034. [PMID: 29951926 DOI: 10.1007/s00535-018-1484-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
8 Khorsandi SE, Salvans S, Zen Y, Agarwal K, Jassem W, Heaton N. Cholangiocarcinoma complicating recurrent primary sclerosing cholangitis after liver transplantation. Transpl Int. 2011;24:e93-e96. [PMID: 21884553 DOI: 10.1111/j.1432-2277.2011.01324.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
9 Folseraas T, Boberg KM. Cancer Risk and Surveillance in Primary Sclerosing Cholangitis. Clin Liver Dis. 2016;20:79-98. [PMID: 26593292 DOI: 10.1016/j.cld.2015.08.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
10 Safarpour AR, Askari H, Ejtehadi F, Azarnezhad A, Raeis-Abdollahi E, Tajbakhsh A, Abazari MF, Tarkesh F, Shamsaeefar A, Niknam R, Sivandzadeh GR, Lankarani KB, Ejtehadi F. Cholangiocarcinoma and liver transplantation: What we know so far? World J Gastrointest Pathophysiol 2021; 12(5): 84-105 [PMID: 34676129 DOI: 10.4291/wjgp.v12.i5.84] [Reference Citation Analysis]
11 Jendrek ST, Gotthardt D, Nitzsche T, Widmann L, Korf T, Michaels MA, Weiss KH, Liaskou E, Vesterhus M, Karlsen TH, Mindorf S, Schemmer P, Bär F, Teegen B, Schröder T, Ehlers M, Hammers CM, Komorowski L, Lehnert H, Fellermann K, Derer S, Hov JR, Sina C. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut 2017;66:137-44. [PMID: 27406039 DOI: 10.1136/gutjnl-2016-311739] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
12 Williamson KD, Chapman RW. Primary sclerosing cholangitis: a clinical update. Br Med Bull. 2015;114:53-64. [PMID: 25981516 DOI: 10.1093/bmb/ldv019] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
13 Chapman MH, Thorburn D, Hirschfield GM, Webster GGJ, Rushbrook SM, Alexander G, Collier J, Dyson JK, Jones DE, Patanwala I, Thain C, Walmsley M, Pereira SP. British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019;68:1356-1378. [PMID: 31154395 DOI: 10.1136/gutjnl-2018-317993] [Cited by in Crossref: 55] [Cited by in F6Publishing: 41] [Article Influence: 18.3] [Reference Citation Analysis]
14 Oster M, Abu-Mouch S, Nachtigal A, Mahamid A, Zeina AR. Segmental hypertrophy mimicking liver tumor in a patient with primary sclerosing cholangitis. J Gastrointest Cancer 2015;46:77-9. [PMID: 25527386 DOI: 10.1007/s12029-014-9678-8] [Reference Citation Analysis]
15 Chapman RW, Williamson KD. Are Dominant Strictures in Primary Sclerosing Cholangitis a Risk Factor for Cholangiocarcinoma? Curr Hepatol Rep. 2017;16:124-129. [PMID: 28706774 DOI: 10.1007/s11901-017-0341-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
16 Restellini S, Chazouillères O, Frossard JL. Hepatic manifestations of inflammatory bowel diseases. Liver Int 2017;37:475-89. [PMID: 27712010 DOI: 10.1111/liv.13265] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
17 Wadsworth CA, Dixon PH, Taylor-Robinson S, Kim JU, Zabron AA, Wong JH, Chapman MH, McKay SC, Spalding DR, Wasan HS, Pereira SP, Thomas HC, Whittaker JC, Williamson C, Khan SA. Polymorphisms in Natural Killer Cell Receptor Protein 2D (NKG2D) as a Risk Factor for Cholangiocarcinoma. J Clin Exp Hepatol 2019;9:171-5. [PMID: 31024198 DOI: 10.1016/j.jceh.2018.06.521] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Saffioti F, Mavroeidis VK. Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis. World J Gastrointest Oncol 2021; 13(10): 1336-1366 [PMID: 34721770 DOI: 10.4251/wjgo.v13.i10.1336] [Reference Citation Analysis]
19 Caillol F, Bories E, Poizat F, Pesenti C, Esterni B, Monges G, Giovannini M. Endomicroscopy in bile duct: Inflammation interferes with pCLE applied in the bile duct: A prospective study of 54 patients. United European Gastroenterol J. 2013;1:120-127. [PMID: 24917949 DOI: 10.1177/2050640613483462] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
20 Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017;67:1298-1323. [PMID: 28802875 DOI: 10.1016/j.jhep.2017.07.022] [Cited by in Crossref: 244] [Cited by in F6Publishing: 209] [Article Influence: 48.8] [Reference Citation Analysis]
21 Rabiee A, Silveira MG. Primary sclerosing cholangitis. Transl Gastroenterol Hepatol 2021;6:29. [PMID: 33824933 DOI: 10.21037/tgh-20-266] [Reference Citation Analysis]
22 Lichtenstein DR. Hepatobiliary complications of inflammatory bowel disease. Curr Gastroenterol Rep. 2011;13:495-505. [PMID: 21773706 DOI: 10.1007/s11894-011-0213-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
23 Jansson H, Olthof PB, Bergquist A, Ligthart MAP, Nadalin S, Troisi RI, Groot Koerkamp B, Alikhanov R, Lang H, Guglielmi A, Cescon M, Jarnagin WR, Aldrighetti L, van Gulik TM, Sparrelid E; Perihilar Cholangiocarcinoma Collaboration Group. Outcome after resection for perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis: an international multicentre study. HPB (Oxford) 2021:S1365-182X(21)00111-8. [PMID: 33975797 DOI: 10.1016/j.hpb.2021.04.011] [Reference Citation Analysis]
24 Barkin JA, Levy C, Souto EO. Endoscopic Management of Primary Sclerosing Cholangitis. Annals of Hepatology 2017;16:842-50. [DOI: 10.5604/01.3001.0010.5274] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
25 Mazza S, Soro S, Verga MC, Elvo B, Ferretti F, Cereatti F, Drago A, Grassia R. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders. World J Hepatol 2021; 13(12): 1828-1849 [DOI: 10.4254/wjh.v13.i12.1828] [Reference Citation Analysis]
26 Culver EL, Chapman RW. Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis. Aliment Pharmacol Ther. 2011;33:1273-1291. [PMID: 21501198 DOI: 10.1111/j.1365-2036.2011.04658.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
27 Chung BK, Karlsen TH, Folseraas T. Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1390-1400. [PMID: 28844951 DOI: 10.1016/j.bbadis.2017.08.020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
28 Giovannini M, Bories E, Monges G, Pesenti C, Caillol F, Delpero JR. Results of a phase I-II study on intraductal confocal microscopy (IDCM) in patients with common bile duct (CBD) stenosis. Surg Endosc. 2011;25:2247-2253. [PMID: 21424206 DOI: 10.1007/s00464-010-1542-8d] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Ehlken H, Zenouzi R, Schramm C. Risk of cholangiocarcinoma in patients with primary sclerosing cholangitis: diagnosis and surveillance. Curr Opin Gastroenterol 2017;33:78-84. [PMID: 28146445 DOI: 10.1097/MOG.0000000000000335] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
30 Zenouzi R, Weismüller TJ, Jørgensen KK, Bubenheim M, Lenzen H, Hübener P, Schulze K, Weiler-normann C, Sebode M, Ehlken H, Pannicke N, Hartl J, Peiseler M, Hübener S, Karlsen TH, Boberg KM, Manns MP, Lohse AW, Schramm C. No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology 2016;14:1806-12. [DOI: 10.1016/j.cgh.2016.07.032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
31 Weismüller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP. The challenges in primary sclerosing cholangitis--aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol. 2008;48 Suppl 1:S38-S57. [PMID: 18304683 DOI: 10.1016/j.jhep.2008.01.020] [Cited by in Crossref: 106] [Cited by in F6Publishing: 93] [Article Influence: 7.6] [Reference Citation Analysis]
32 Goode EC, Rushbrook SM. A review of the medical treatment of primary sclerosing cholangitis in the 21st century. Ther Adv Chronic Dis 2016;7:68-85. [PMID: 26770670 DOI: 10.1177/2040622315605821] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
33 Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology 2021:S0016-5085(21)03337-0. [PMID: 34358489 DOI: 10.1053/j.gastro.2021.07.042] [Reference Citation Analysis]
34 Sandhu DS, Roberts LR. Diagnosis and management of cholangiocarcinoma. Curr Gastroenterol Rep 2008;10:43-52. [DOI: 10.1007/s11894-008-0008-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
35 de Martel C, Plummer M, Franceschi S. Cholangiocarcinoma: descriptive epidemiology and risk factors. Gastroenterol Clin Biol. 2010;34:173-180. [PMID: 20202771 DOI: 10.1016/j.gcb.2010.01.008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
36 Navaneethan U. Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk. Gastroenterol Rep (Oxf). 2014;2:193-200. [PMID: 24951514 DOI: 10.1093/gastro/gou036] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
37 Petersen BT. Cholangioscopy for Special Applications: Primary Sclerosing Cholangitis, Liver Transplant, and Selective Duct Access. Gastrointestinal Endoscopy Clinics of North America 2009;19:579-86. [DOI: 10.1016/j.giec.2009.06.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
38 Parian A, Lazarev M. Who and how to screen for cancer in at-risk inflammatory bowel disease patients. Expert Rev Gastroenterol Hepatol 2015;9:731-46. [PMID: 25592672 DOI: 10.1586/17474124.2015.1003208] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
39 Silveira MG, Lindor KD. Primary Sclerosing Cholangitis. In: Monga SPS, editor. Molecular Pathology of Liver Diseases. Boston: Springer US; 2011. pp. 741-52. [DOI: 10.1007/978-1-4419-7107-4_50] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 Maggs JR, Chapman RW. An update on primary sclerosing cholangitis: . Current Opinion in Gastroenterology 2008;24:377-83. [DOI: 10.1097/mog.0b013e3282f9e239] [Cited by in Crossref: 86] [Cited by in F6Publishing: 17] [Article Influence: 6.1] [Reference Citation Analysis]
41 Gossard AA, Lindor KD. A 42–Year–Old Woman With a New Diagnosis of Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology 2012;10:593-7. [DOI: 10.1016/j.cgh.2012.02.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Fung BM, Tabibian JH. Biliary endoscopy in the management of primary sclerosing cholangitis and its complications. Liver Res 2019;3:106-17. [PMID: 31341699 DOI: 10.1016/j.livres.2019.03.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
43 Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013;145:521-36. [PMID: 23827861 DOI: 10.1053/j.gastro.2013.06.052] [Cited by in Crossref: 223] [Cited by in F6Publishing: 196] [Article Influence: 24.8] [Reference Citation Analysis]
44 Larsen S, Bendtzen K, Nielsen OH. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Ann Med. 2010;42:97-114. [PMID: 20166813 DOI: 10.3109/07853890903559724] [Cited by in Crossref: 172] [Cited by in F6Publishing: 148] [Article Influence: 14.3] [Reference Citation Analysis]
45 Seo KI, Kang SB. [Hepatobiliary Manifestation of Inflammatory Bowel Disease]. Korean J Gastroenterol 2019;73:248-59. [PMID: 31132831 DOI: 10.4166/kjg.2019.73.5.248] [Reference Citation Analysis]
46 Silveira MG, Lindor KD. Clinical features and management of primary sclerosing cholangitis. World J Gastroenterol 2008; 14(21): 3338-3349 [PMID: 18528931 DOI: 10.3748/wjg.14.3338] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
47 Buckholz AP, Brown RS Jr. Cholangiocarcinoma: Diagnosis and Management. Clin Liver Dis 2020;24:421-36. [PMID: 32620281 DOI: 10.1016/j.cld.2020.04.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
48 Trivedi PJ, Chapman RW. PSC, AIH and overlap syndrome in inflammatory bowel disease. Clin Res Hepatol Gastroenterol. 2012;36:420-436. [PMID: 22306055 DOI: 10.1016/j.clinre.2011.10.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
49 Soejima Y, Ueda S, Sanefuji K, Kayashima H, Yoshizumi T, Ikegami T, Yamashita Y, Sugimachi K, Iguchi T, Taketomi A, Maehara Y. Sequential Pancreaticoduodenectomy after Living Donor Liver Transplantation for Cholagiocacinoma. American Journal of Transplantation 2008;8:2158-62. [DOI: 10.1111/j.1600-6143.2008.02346.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
50 Fung BM, Tabibian JH. Primary sclerosing cholangitis-associated cholangiocarcinoma: special considerations and best practices. Expert Rev Gastroenterol Hepatol 2021;15:487-96. [PMID: 33682586 DOI: 10.1080/17474124.2021.1900732] [Reference Citation Analysis]
51 Veillette G, Castillo CF. Distal Biliary Malignancy. Surgical Clinics of North America 2008;88:1429-47. [DOI: 10.1016/j.suc.2008.07.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
52 Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185. [PMID: 24901008 DOI: 10.1155/2014/149185] [Cited by in Crossref: 715] [Cited by in F6Publishing: 748] [Article Influence: 89.4] [Reference Citation Analysis]
53 Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29:221-232. [PMID: 25966423 DOI: 10.1016/j.bpg.2015.02.003] [Cited by in Crossref: 190] [Cited by in F6Publishing: 169] [Article Influence: 27.1] [Reference Citation Analysis]
54 Dohan A, Faraoun S, Barral M, Guerrache Y, Boudiaf M, Dray X, Hoeffel C, Allez M, Farges O, Beaugerie L, Aparicio T, Marteau P, Fishman E, Lucidarme O, Eveno C, Pocard M, Dautry R, Soyer P. Extra-intestinal malignancies in inflammatory bowel diseases: An update with emphasis on MDCT and MR imaging features. Diagnostic and Interventional Imaging 2015;96:871-83. [DOI: 10.1016/j.diii.2015.02.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
55 Verslype C, Libbrecht L. The diagnostic and therapeutic approach for primary solid liver tumours in adults. Best Practice & Research Clinical Gastroenterology 2007;21:983-96. [DOI: 10.1016/j.bpg.2007.09.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
56 Chapman R, Williamson K. Primary Sclerosing Cholangitis. The Digestive Involvement in Systemic Autoimmune Diseases. Elsevier; 2017. pp. 119-39. [DOI: 10.1016/b978-0-444-63707-9.00007-6] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
57 Fevery J, Verslype C. An update on cholangiocarcinoma associated with primary sclerosing cholangitis. Curr Opin Gastroenterol. 2010;26:236-245. [PMID: 20216413 DOI: 10.1097/mog.0b013e328337b311] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
58 Fung BM, Tabibian JH. Cholangiocarcinoma in patients with primary sclerosing cholangitis.Curr Opin Gastroenterol. 2020;36:77-84. [PMID: 31850928 DOI: 10.1097/MOG.0000000000000616] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
59 Nikeghbalian S, Shamsaeefar A, Eshraghian A, Mansoorian MR, Kazemi K, Geramizadeh B, Malek-hosseini SA. Liver transplantation and whipple surgery combined with chemoradiotherapy for treatment of hilar cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver Transpl 2015;21:696-9. [DOI: 10.1002/lt.24095] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
60 Hajj IIE, Dewitt JM, Coté GA. Diagnosis and Staging of Premalignant and Early Malignant Diseases. In: Deutsch JC, Banks MR, editors. Gastrointestinal Endoscopy in the Cancer Patient. Oxford: John Wiley & Sons, Ltd; 2013. pp. 191-204. [DOI: 10.1002/9781118555651.ch18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
61 Fung BM, Lindor KD, Tabibian JH. Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. World J Gastroenterol 2019; 25(6): 659-671 [PMID: 30783370 DOI: 10.3748/wjg.v25.i6.659] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 26] [Article Influence: 13.7] [Reference Citation Analysis]
62 Lee JJ, Schindera ST, Jang HJ, Fung S, Kim TK. Cholangiocarcinoma and its mimickers in primary sclerosing cholangitis. Abdom Radiol (NY) 2017;42:2898-908. [PMID: 28951947 DOI: 10.1007/s00261-017-1328-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
63 Fevery J, Henckaerts L, Van Oirbeek R, Vermeire S, Rutgeerts P, Nevens F, Van Steenbergen W. Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long-term single-centre study. Liver Int. 2012;32:214-222. [PMID: 21745316 DOI: 10.1111/j.1478-3231.2011.02575.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 5.3] [Reference Citation Analysis]
64 Boberg KM, Lind GE. Primary sclerosing cholangitis and malignancy. Best Pract Res Clin Gastroenterol. 2011;25:753-764. [PMID: 22117640 DOI: 10.1016/j.bpg.2011.10.002] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 5.7] [Reference Citation Analysis]
65 Van Beers BE. Diagnosis of cholangiocarcinoma. HPB (Oxford). 2008;10:87-93. [PMID: 18773062 DOI: 10.1080/13651820801992716] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
66 Tabibian JH, Ali AH, Lindor KD. Primary Sclerosing Cholangitis, Part 2: Cancer Risk, Prevention, and Surveillance. Gastroenterol Hepatol (NY). 2018;14:427-432. [PMID: 30166959 DOI: 10.6000/1927-7229.2012.01.01.7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
67 Song J, Li Y, Bowlus CL, Yang G, Leung PSC, Gershwin ME. Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review. Clin Rev Allergy Immunol. 2020;58:134-149. [PMID: 31463807 DOI: 10.1007/s12016-019-08764-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
68 Gidwaney NG, Pawa S, Das KM. Pathogenesis and clinical spectrum of primary sclerosing cholangitis. World J Gastroenterol 2017; 23(14): 2459-2469 [PMID: 28465630 DOI: 10.3748/wjg.v23.i14.2459] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
69 Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1598-1619. [PMID: 20198712 DOI: 10.1002/ibd.21219] [Cited by in Crossref: 133] [Cited by in F6Publishing: 115] [Article Influence: 11.1] [Reference Citation Analysis]
70 Schöning W, Schmeding M, Ulmer F, Andert A, Neumann U. Liver Transplantation for Patients with Cholestatic Liver Diseases. Viszeralmedizin 2015;31:194-8. [PMID: 26468315 DOI: 10.1159/000431017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
71 Wannhoff A, Gotthardt DN. Recent developments in the research on biomarkers of cholangiocarcinoma in primary sclerosing cholangitis. Clin Res Hepatol Gastroenterol. 2018;pii:S2210-7401(18)30177-3. [PMID: 30266579 DOI: 10.1016/j.clinre.2018.08.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
72 Brown SR, Coviello LC. Extraintestinal Manifestations Associated with Inflammatory Bowel Disease. Surg Clin North Am. 2015;95:1245-159, vii. [PMID: 26596925 DOI: 10.1016/j.suc.2015.08.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
73 Bhatia K, Mok G, Lin K, Choi F. A diffuse branching pattern of biliary FDG activity: infective or neoplastic? Rev Esp Med Nucl Imagen Mol 2012;31:165-6. [PMID: 22056001 DOI: 10.1016/j.remn.2011.08.006] [Reference Citation Analysis]
74 Giovannini M, Bories E, Monges G, Pesenti C, Caillol F, Delpero JR. Results of a phase I-II study on intraductal confocal microscopy (IDCM) in patients with common bile duct (CBD) stenosis. Surg Endosc. 2011;25:2247-2253. [PMID: 21424206 DOI: 10.1007/s00464-010-1542-8] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 5.0] [Reference Citation Analysis]
75 Terjung B, Spengler U. Atypical p-ANCA in PSC and AIH: a hint toward a "leaky gut"? Clin Rev Allergy Immunol. 2009;36:40-51. [PMID: 18626795 DOI: 10.1007/s12016-008-8088-8] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
76 Lutz H, Trautwein C, Tischendorf JW. Primary sclerosing cholangitis: diagnosis and treatment. Dtsch Arztebl Int 2013;110:867-74. [PMID: 24529302 DOI: 10.3238/arztebl.2013.0867] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
77 Özdirik B, Müller T, Wree A, Tacke F, Sigal M. The Role of Microbiota in Primary Sclerosing Cholangitis and Related Biliary Malignancies. Int J Mol Sci 2021;22:6975. [PMID: 34203536 DOI: 10.3390/ijms22136975] [Reference Citation Analysis]
78 Mala A, Foteinogiannopoulou K, Koutroubakis IE. Solid extraintestinal malignancies in patients with inflammatory bowel disease. World J Gastrointest Oncol 2021; 13(12): 1956-1980 [DOI: 10.4251/wjgo.v13.i12.1956] [Reference Citation Analysis]
79 Barner-rasmussen N, Pukkala E, Jussila A, Färkkilä M. Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. Scandinavian Journal of Gastroenterology 2020;55:74-81. [DOI: 10.1080/00365521.2019.1707277] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]